Vllaho, A.-M. | bioRxiv Science

bioRxiv2026

Reversing PROTAC-induced ASH2L degradation reactivates proliferation in senescent cells

Nucleosomes control access to gene promoters. Histone H3 lysine 4 tri-methylation, catalyzed by 6 KMT2 complexes, correlates with accessible promoters and gene expression. The catalytic activity of KMT2 enzymes depends on an obligatory core complex with ASH2L being an essential subunit. We find that PROTAC induced depletion of ASH2L reduces H3K4me3, deregulates gene expression and prevents proliferation. Upon prolonged ASH2L loss, cells develop a senescent phenotype, a process linked to aging and disease. Competing the PROTAC reactivates ASH2L, reestablishes H3K4me3 at promoters and reverts gene expression changes. Cells reenter the cell cycle and resume proliferation, thereby reverting senescence. Structure-function studies demonstrate that these molecular and cellular consequences are primarily due to the loss of ASH2L functions associated with KMT2 complexes. Together, these findings indicate that stress inflicted by the loss of KMT2 catalytic activities promotes a reversible senescence phenotype, suggesting that the functions of KMT2 complexes are implicated in aging. Graphical abstract O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=127 SRC="FIGDIR/small/722411v1_ufig1.gif" ALT="Figure 1"> View larger version (30K): org.highwire.dtl.DTLVardef@10ace2forg.highwire.dtl.DTLVardef@667c81org.highwire.dtl.DTLVardef@78039dorg.highwire.dtl.DTLVardef@13563be_HPS_FORMAT_FIGEXP M_FIG C_FIG

cell biology↗

bioRxiv2026

Polyploid cardiomyocytes define disease-specific transcriptional states in the mammalian heart

The adult mammalian heart has a limited regenerative capacity. Following injury, cardiomyocytes undergo a hypertrophic response accompanied by polyploidization, which has been described as a barrier to proliferation and regeneration of the heart1,2. However, the unique molecular programs of polyploidy, or genome multiplied cardiomyocytes, and their influence on the disease-related myocardial remodelling process remains unclear. Here, we integrate single-nuclei and high-resolution spatial multi-omics across human, rat, and mouse hearts to define novel cardiac cell states and their tissue niches in ischemic and non-ischemic heart disease. Computational analysis across scales allowed us to generate detailed networks of the cardiac tissue remodelling process as well as tissue and sub-cellular environments uniquely enriched in polyploid cardiomyocytes or their diploid origins. We identify a conserved, dichotomous transcriptional program distinguishing diploid from polyploid cardiomyocytes. Polyploid cardiomyocytes demonstrated rewired metabolic and chromatin-remodeling transcriptional programs and recapitulate the gene signature of immature human fetal cardiomyocytes. Notably, we observe that polyploid cardiomyocytes--rather than the general myocyte population--are the primary sites of enrichment for major heart-failure drug targets, including the mineralocorticoid, {beta}1-adrenergic, and glucagon-like peptide-1 receptors. Based on our cross-species dataset we further identified TNIK, a Wnt-pathway regulator expressed in polyploid cardiomyocytes across species, as a potential therapeutic target and demonstrate that pharmacological TNIK inhibition improves cardiac function after myocardial infarction in rats. Together, this species-spanning, disease-resolved study redefines cardiomyocyte heterogeneity in heart disease and suggests a therapeutic path to heart failure treatment by targeting polyploid cardiomyocytes.

genomics↗